Products

EntrolyticsMD
Motilent
Gastroenterology AI
EntrolyticsMD by Motilent is an FDA-listed, secure, cloud-based medical imaging platform optimized for gastrointestinal data, enabling clinicians to review multi-modality studies and integrate AI analysis tools for digestive diseases.
GIQuant
Motilent
Gastroenterology AI
GIQuant by Motilent is an FDA-cleared AI medical image analysis software that quantifies intestinal motility from MRI scans, primarily for assessing digestive diseases like Crohn's disease, aiding in diagnosis, monitoring, and treatment response.

See all 2 products →

About Motilent

Motilent is a pioneering healthcare AI company specializing in the assessment of digestive diseases through advanced medical image analysis. The company’s core mission is to transform the understanding of the gastrointestinal (GI) system for academic, life sciences, and clinical communities, ultimately improving the lives of patients with digestive diseases.

Their flagship product, GIQuant®, is a CE-marked and FDA-cleared post-processing software that works in conjunction with standard magnetic resonance imaging (MRI) scans. GIQuant quantifies motion in dynamic abdominal MRI data, providing physicians with specialized measurements and advanced analysis of the bowel wall. This technology is particularly valuable in assessing treatment response in inflammatory bowel disease (IBD), including Crohn’s disease, by measuring and tracking intestinal movement. The degree of bowel inflammation often correlates with reduced motility, offering insights into disease progression and treatment efficacy. By providing non-invasive, data-led insights, GIQuant aims to help clinicians identify ineffective treatments faster and accelerate the treatment journey for patients.

Motilent is actively engaged in research related to various gastrointestinal conditions beyond IBD, such as constipation, gastroparesis, and Irritable Bowel Syndrome (IBS). They are committed to groundbreaking research in collaboration with international partners and are enthusiastic about the potential of non-invasive gastroenterology technologies, including MRI, ultrasound, and capsule endoscopy.

What Physicians Need to Know

Specialization
Motilent specializes in AI medical image analysis for digestive diseases, with a primary focus on inflammatory bowel disease (IBD), particularly Crohn's disease. They also engage in projects related to constipation, gastroparesis, and IBS.
Key Product: GIQuant
GIQuant is a post-processing application that uses AI to quantify motion in dynamic abdominal MRI data, providing an objective score for small bowel motility. This helps in assessing treatment response and disease progression in Crohn's disease.
Key Product: Entrolytics
Entrolytics is Motilent's secure, cloud-based medical imaging platform optimized for gastrointestinal data. It allows for organizing, analyzing, and collaborating on multi-modality data (MRI, ultrasound, endoscopy, video) in one place.
Key Product: vEUA
vEUA (Virtual Examination Under Anaesthetic) is a 3D modeling technology that creates anatomically representative models from MRI scans, aiding in the visualization of complex pelvic and perineal diseases for surgical planning and patient communication.
Key Product: Bridge
Bridge is a solution for capturing, storing, and sharing intestinal ultrasound (IUS) data, designed to streamline workflows for clinical trials, routine practice, and education.
Regulatory Clearances
Motilent's GIQuant has received FDA 510(k) clearance in the USA and CE certification (Class IIa) in Europe.
Technology Stack
Their core technology involves AI medical image analysis, specifically using image registration to quantify motion in dynamic MRI data. Their platforms are cloud-based and designed for handling large, complex, multi-modality gastrointestinal datasets.
Research and Collaboration
Motilent originated from King's College London and University College London (UCL) and is committed to groundbreaking research in collaboration with international partners, focusing on non-invasive gastroenterology technologies.
Physician Tip

For physicians, Motilent's tools offer objective, data-led insights into digestive diseases, particularly Crohn's. GIQuant provides a rapid, objective score for small bowel motility, helping to monitor therapeutic response and make more informed treatment decisions, potentially taking patients off ineffective therapies faster. Entrolytics streamlines the review of multi-modality studies, offering quantitative metrics and facilitating collaboration. vEUA provides clear, interactive 3D visualizations for surgical planning and patient communication. These tools aim to reduce subjectivity in image interpretation, improve patient outcomes, and support efficient clinical trials.

Motilent has partnered with Nuance AI solutions for the rollout of their technology in the U.S., leveraging Nuance's presence in 90% of hospitals and 80% of U.S. radiologists. Their platforms, like Entrolytics, are designed to host and integrate with both proprietary and third-party AI image analysis tools, and export images and annotations in standardized formats (e.g., DICOM + JSON) to support interoperability with external systems. GIQuant is also designed to be integrated within a DICOM compliant workflow server, with outputs viewable in standard DICOM viewers.

Products by Motilent

2 products in the directory

EntrolyticsMD
Motilent
Gastroenterology AI
EntrolyticsMD by Motilent is an FDA-listed, secure, cloud-based medical imaging platform optimized for gastrointestinal data, enabling clinicians to review multi-modality studies and integrate AI analysis tools for digestive diseases.
GIQuant
Motilent
Gastroenterology AI
GIQuant by Motilent is an FDA-cleared AI medical image analysis software that quantifies intestinal motility from MRI scans, primarily for assessing digestive diseases like Crohn's disease, aiding in diagnosis, monitoring, and treatment response.

What the Web Says

Motilent is a medical technology company specializing in MRI-based body imaging analysis, particularly for gastrointestinal motility. They develop technology that can be integrated into healthcare provider systems to aid in the evaluation of conditions like Crohn's disease. The company is based in London, UK, and has between 11 and 50 employees.

Overall: Mixed

Strengths

  • Specializes in MRI-based body imaging analysis for gastrointestinal issues.
  • Technology can be integrated into existing healthcare systems.
  • Focus on aiding in the evaluation of conditions like Crohn's disease.
  • Small company size may offer a close-knit work environment.

Limitations

  • Limited public reviews available, making it difficult to gauge widespread sentiment.
  • No specific product or employer reviews found on major platforms like G2, Glassdoor, Capterra, or Reddit.
  • Information on company culture, salaries, and benefits is not readily available from employee reviews.

Based on reviews from: SimplyHired, Indeed.com, Google Scholar, American College of Radiology (ACR)

Last updated: 2026-10-21

Videos

News, demos, and interviews about Motilent.

Loading videos...

Videos load interactively. If none appear, search YouTube for Motilent →

View all on YouTube

Press & Coverage

Digital Health
Motilent secures additional funding for bowel care technology
Motilent received additional funding from the National Institute for Health and Care Research (NIHR) to develop and roll out technology providing data-led insights into inflammatory bowel disease and Crohn's disease. This funding will support the rollout of GiQuant to NHS hospitals.
2022-05
Tech Funding News
Motilent raises £1.2M to rollout its CE-marked GIQuant software — TFN
Motilent, a company specializing in AI medical image analysis for digestive diseases, secured £1.2 million in NIHR funding to support the rollout of its CE-marked GIQuant software.
2022-05
PR Newswire
Motilent takes on the US with FDA clearance and national hospital partnership
Motilent announced FDA 510K clearance in the USA for its AI medical image analysis software, GIQuant, for assessing digestive diseases. The rollout will be in partnership with Nuance AI solutions.
2021-11
AuntMinnie
FDA clears Motilent's AI gastrointestinal imaging software
The U.S. Food and Drug Administration (FDA) has cleared Motilent's AI-based gastrointestinal imaging software, GIQuant, which measures and tracks intestinal movement using MRI exams.
2021-11
Motilent
Motilent and IBDrelief to define and deliver a new standard for IBD care.
Motilent has acquired IBDrelief, aiming to combine cutting-edge technology with patient-centric education to redefine standards in managing Crohn's disease and ulcerative colitis.
2025-02
Motilent
Motilent's EntrolyticsMD is now ready for clinical use in the United States.
Motilent announced that its EntrolyticsMD software is now ready for clinical use in the United States, expanding its innovative solutions for gut imaging.
2024-03
Minerva Imaging
Motilent Limited and Minerva Imaging announce a strategic partnership to re-envision digestive disease research
Motilent and Minerva Imaging have formed a strategic partnership to advance digestive disease research through preclinical investigation and new treatment modalities.
2023-06
Motilent Publications
MRI-Based Characterization of Intestinal Motility in Children and Young Adults With Newly Diagnosed Ileal Crohn Disease Treated by Biologic Therapy: A Controlled Prospective Study
This peer-reviewed study characterizes intestinal motility using MRI in pediatric and young adult patients with newly diagnosed ileal Crohn's disease undergoing biologic therapy.
unknown

Frequently Asked Questions

Motilent's main AI product is GIQuant, a software that analyzes MRI scans to measure and track intestinal motility, primarily for assessing Crohn's disease activity and treatment response. They also offer Entrolytics, a secure, cloud-based platform for managing and analyzing gastrointestinal imaging data, and Bridge, a solution for capturing and sharing intestinal ultrasound data.
Motilent's Entrolytics platform is built on ISO-27001 infrastructure and is designed for HIPAA and GDPR compliance, including features for de-identification and the 'right to be forgotten.' Their GIQuant product is FDA cleared (Class II) and CE Marked (Class IIa), indicating it meets regulatory standards for medical devices in the US and Europe.
Specific pricing details for Motilent's AI products are not publicly available. However, custom reports may involve an implementation cost, though existing reports might be available at a low to no cost depending on the project and resources. Their technology is rolled out in partnership with Nuance AI solutions in the US, suggesting an acquisition model through this partnership.
While detailed support structures are not explicitly outlined, Motilent aims to streamline clinical practice, research, and clinical trials through its platforms. Their partnership with Nuance Communications, which serves a large percentage of hospitals and radiologists, suggests integration and support would be part of that collaboration.
Motilent has a significant partnership with Nuance AI solutions for the rollout of its GIQuant software in the USA. Nuance's extensive reach in hospitals and healthcare organizations allows Motilent's technology to be deployed widely and integrate with existing clinical decision-making processes. Motilent also collaborates with academic institutions like King's College London and University College London, where it originated.
Motilent was launched in 2013 by Dr. Alex Menys, an alumnus of King's College London and University College London. The company has received funding, including grants from the National Institute for Health and Care Research (NIHR) in the UK, totaling over £1.2 million for the development and rollout of GIQuant. They have been actively involved in numerous projects worldwide and have processed over 100,000 images.
Motilent's GIQuant software is clinically validated and supported by multiple peer-reviewed studies. Research indicates that GIQuant scores correlate with inflammation and treatment response in Crohn's disease, and changes in motility can be detected before visible structural changes on MRI. It has also been adopted as an imaging endpoint in multi-center Crohn's disease trials.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.